Westport, Connecticut-based Intensity Therapeutics was a notable IPO in 2023. The company began trading on the Nasdaq Capital Market on June 30, 2023, coinciding with a capital raise of $20.5-million, led by The Benchmark Company and Freedom Capital Markets. The company raised the capital at a share price of $5.00.
Intensity Therapeutics is a biotechnology company that focuses on the development of cancer therapeutics. The company’s main approach is to develop direct tumor injection methods that cause cancer cell death and simultaneously enable an anti-cancer immune response. This could potentially lead to the elimination of untreated tumors and metastases at other locations in the body.
One of the notable drugs in development by Intensity Therapeutics, as of my last update in January 2022, is INT230-6. This drug is designed to treat solid tumors by dispersing through cancerous cells upon injection and inducing cell death, while also facilitating the uptake of the cancer cell’s antigens by dendritic cells. This uptake can then potentially initiate a broader immune system response against the cancer.
The company’s methods represent a segment of the broader field of immuno-oncology, where research and treatments are aimed at harnessing the body’s immune system to fight cancer.
However, for the most recent updates or detailed information about Intensity Therapeutics, its ongoing clinical trials, or other developments, you may want to refer to the company’s official website, press releases, or relevant regulatory filings.
Is INTS stock a buy?
According to MarketWatch, the average stock price forecast on INTS is $12.00, implying a return of 181.7 per cent. However, the stock is covered by a single analyst who has a “Buy” rating on it.
But according to Nasdaq.com, the rating on the stock is from Benchmark Capital and is a “Speculative Buy”, which was reiterated on August 24,2023.
The next earnings date on the stock in Monday, November 13, 2023.
What does Intensity Therapeutics do? (via Compay handout)
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRx℠ technology platform to create proprietary drug formulations that following direct injection rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity’s product candidates have the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors. The Company’s lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. Intensity has a clinical collaboration agreement with Merck Sharpe & Dohme (Merck) to evaluate INT230-6 with pembrolizumab. In addition, the Company has a clinical collaboration agreement with Bristol-Myers Squibb to evaluate the combination INT230-6 with Bristol-Myers Squibb’s anti-CTLA-4 antibody, ipilimumab. Intensity has also executed agreements with the Ottawa Hospital Research Institute (OHRI) and the Ontario Institute of Cancer Research (OICR) to study INT230-6 in a randomized controlled neoadjuvant phase 2 study in women with early stage breast cancer (the INVINCIBLE study) (NCT04781725). Additionally, the Company executed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s (NCI) Vaccine Branch
We Hate Paywalls Too!
At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.